Tina DiMarcantonio Brown

Philadelphia

Executive Editor at HealthDay

Managing Editor, Physician's Briefing, @HealthDayTweets

Featured in: Favicon

healthday.com Favicon

telegraph.co.uk Favicon

healio.com Favicon

medicalxpress.com Favicon

sfexaminer.com Favicon

kdhnews.com Favicon

djournal.com Favicon

kxly.com

wfmz.com

channel3000.com + 87 more

Articles

FDA Approves First At-Home Test to Diagnose Three STIs in Women

3 weeks ago | healthday.com | Tina DiMarcantonio Brown

Published on: Apr 01, 2025, 8:53 pmUpdated on: Apr 01, 2025, 8:53 pmLoading content, please wait...
Trump Issues Executive Order Withdrawing U.S. From WHO

Jan 22, 2025 | healthday.com | Tina DiMarcantonio Brown

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- In one of his first presidential actions on Monday, President Trump issued an executive order withdrawing the United States from the World Health Organization. The executive order retracts a Presidential Letter by President Biden on Jan. 20, 2021, revoking the original withdrawal by Trump in his last term on July 6, 2020.
ECTRIMS 2024 Conference Summary Featuring Cristina Granziera, MD, PHD, Executive Committee of ECTRIMS and Dr. David Hafler, Chairman Department of Neurology at Yale School of Medicine

Oct 1, 2024 | healthday.com | Tina DiMarcantonio Brown

Hi, I'm Cristina Granziera. I'm part of a member of the Executive Committee of ECTRIMS. I'm also a neurologist, clinically active at the University Hospital Basel, and I'm co-directing the Research Center for Clinical Neuroimmunology and Neuroscience in Basel. So ECTRIMS this year was a special ECTRIMS because it was the 40th anniversary of the conference.
European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20

Sep 27, 2024 | healthday.com | Tina DiMarcantonio Brown

The annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis was held from Sept. 18 to 20 in Copenhagen, Denmark, and drew more than 8,500 delegates from around the world, including clinicians and researchers in multiple sclerosis (MS).
2024 ASCO Annual Meeting to Focus on Clinical Cancer Research Impacting Patient Care

May 23, 2024 | healthday.com | Tina DiMarcantonio Brown

THURSDAY, May 23, 2024 (HealthDay News) -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held May 31 to June 4, 2024, in Chicago and online. The theme of this year's meeting is The Art and Science of Cancer Care: From Comfort to Cure. Attendees will share and discuss the latest clinical cancer research impacting patient care.
AAD: Lebrikizumab Shows Efficacy in Skin-of-Color Patients With Atopic Dermatitis

Mar 18, 2024 | healthday.com | Tina DiMarcantonio Brown |Mark Arredondo

MONDAY, March 18, 2024 (HealthDay News) -- Lebrikizumab demonstrates improvement in skin clearance and itch relief in patients with skin of color and moderate-to-severe atopic dermatitis, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 8 to 12 in San Diego.
AAD: Hair Regrowth Continues to Improve at 76 Weeks With Baricitinib for Severe Alopecia

Mar 18, 2024 | healthday.com | Tina DiMarcantonio Brown |Mark Arredondo

MONDAY, March 18, 2024 (HealthDay News) -- Continuous treatment with baricitinib in patients with severe alopecia areata demonstrates improvement in hair regrowth outcomes through 76 weeks of follow-up, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 8 to 12 in San Diego. Rodney D.
AAD: Adult Acne Clinic Visits Increase With Exposure to Wildfire-Related Air Pollution

Mar 15, 2024 | healthday.com | Tina DiMarcantonio Brown |Mark Arredondo

FRIDAY, March 15, 2024 (HealthDay News) -- Short-term exposure to wildfire-related air pollution is associated with an increase in clinic visits for acne vulgaris among adults, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 8 to 10 in San Diego. Alex Ha, from the University of California, San Francisco, and colleagues conducted a retrospective cohort study to determine environmental triggers and factors for acne vulgaris.
AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis

Mar 15, 2024 | healthday.com | Tina DiMarcantonio Brown |Mark Arredondo

FRIDAY, March 15, 2024 (HealthDay News) -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are durable at four years, according to research presented at the annual meeting of the American Academy of Dermatology, held from March 8 to 10 in San Diego.
米FDAが多発性硬化症治療薬のバイオシミラーを初承認

Sep 11, 2023 | consumer.healthday.com | Tina DiMarcantonio Brown

×Fact CheckedHealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy. All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Coverage map

X (formerly Twitter)

Followers: 35
Tweets: 86
DMs Open: No

Tina DiMarcantonio Brown @TinaDiMarcanto1

18 May 22

RT @HealthDayTweets: Join us this Thursday for a special webinar discussion with Stacey D. Stewart of @marchofdimes on the risks that pregn…

Tina DiMarcantonio Brown @TinaDiMarcanto1

24 Mar 22

RT @HealthDayTweets: Did you know that heart disease is the number one leading cause of death among women? Key experts including @ditchhapo…

Tina DiMarcantonio Brown @TinaDiMarcanto1

1 Mar 22

RT @HealthDayTweets: RSVP for our #webinar to explore how mobile apps are helping people manage disease https://t.co/I6zp7RtjZP - Broadcast…

Tina DiMarcantonio Brown

Articles

FDA Approves First At-Home Test to Diagnose Three STIs in Women

Trump Issues Executive Order Withdrawing U.S. From WHO

ECTRIMS 2024 Conference Summary Featuring Cristina Granziera, MD, PHD, Executive Committee of ECTRIMS and Dr. David Hafler, Chairman Department of Neurology at Yale School of Medicine

European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20

2024 ASCO Annual Meeting to Focus on Clinical Cancer Research Impacting Patient Care

AAD: Lebrikizumab Shows Efficacy in Skin-of-Color Patients With Atopic Dermatitis

AAD: Hair Regrowth Continues to Improve at 76 Weeks With Baricitinib for Severe Alopecia

AAD: Adult Acne Clinic Visits Increase With Exposure to Wildfire-Related Air Pollution

AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis

米FDAが多発性硬化症治療薬のバイオシミラーを初承認

Contact details

Emails

Socials & Sites

Coverage map

X (formerly Twitter)